Updates of portal HTN guidance statement by
@ggarciatsao
🔺CSPH can be defined by
📍Collaterals on imaging
📍EV on endoscopy
📍LS>25, LS 20-25/Plt<150
🔺Carvedilol is the NSBB of choice 6.25-12.5 daily
🔺Goal is prevention of decompensation in the new…
🚀new practice guidance on management of portal HTN from
@AASLDtweets
is here
📍concept of cACLD
📍noninvasive assessments of CSPH
📍change in paradigm & early use of NSBB to prevent decompensation
📍preemptive TIPS
Keep calm on beta block your patients ❤️
#livertwitter
…
I usually don’t share anything personal, but this meant a lot to me.
My colleagues and friends at work celebrated my BD in the midst of a pandemic. There is still so much good in this 🌎❤️
#WeAreAllInThisTogether
🧵
In acute variceal 🩸
New statements 👇
- use vasoactive drugs at least 2 and up to 5 days
- oral nutrition should be started ASAP
- 🛑 PPI immediately after EGD if no strict indication
- Hemostatic powder NOT recommended as first line for AVB
#livertwitter
@BavenoVII
📢 New GI fellows:
You want to book mark this 👇🏼
Iron deficiency anemia is a very common consult and could be annoying at times, but needs critical thinking and a step wise approach
#GItwitter
@AmerGastroAssn
Updates on interventional treatment of portal HTN by
@JuanAbraldes
🔺First review pic 👇🏼
🔺start TIPS at 8 mmHg with goal below 12 (between PV and IVC)
🔺if pressure not below 12 with dilation to 10 mm, add NSBB
🔺see table 👇🏼for contraindications
#TLM23
#livertwitter
…
If you want to change behavior, show the data. So proud of
@RabieeAnahita
adding to evidence behind safety of naltrexone in cirrhosis.
Among 2940 patients with cirrhosis started on naltrexone for AUD, zero cases of DILI was identified!
#livertwitter
📢Albumin is on the news again!
In this open-label study led by
#ShivSarin
, critically-ill cirrhosis pts were randomized to 20% albumin or plasmalyte with primary end-point of MAP> 65 at 3 hrs
⚠️Results 👇🏼👇🏼👇🏼
#livertwitter
@JHepatology
Great talk by Dr. Dieterich
📌HBV carrier is a misnomer
📌 most patients with CHB fall into grey zone based on current guidelines
📌 ⬆️DNA levels is a/w ⬆️ risk of cirrhosis & HCC
📌 a proposed treatment algorithm : treat the 🦠 NOT ALT
#liverMTg21
#livertwitter
@AASLDtweets
Long 🧵
#livertwitter
#gitwitter
1/6
I feel detached from my body in the morning, when I go to the hospital, round with the team, see new consults, attend meetings.
Then I check my social media which takes me back to my life before.
#Mahsa_Amini
🔥 off the press
Long anticipated
#NAFLD
practice guidance
🎯use FIB-4 in high risk patients: T2DM, MetSyn, alcohol use
🎯ELF or TE as second step
🎯Multidisciplinary care is 🔑
#livertwitter
@AASLDtweets
@DrLoomba
⚠️AC for portal vein thrombosis in cirrhosis?
This recent meta-analysis showed ⬇️⬇️⬇️ all cause mortality
There was ⬆️⬆️⬆️ in non-portal HTN 🩸
‼️Benefit independent of severity or recanalization
#livertwitter
@JHepatology
@ReibergerThomas
When liver is a bystander….
1/3
At least once a month, this ❓comes up on consult; why are liver enzymes
abnormal in ICU patients?
🔹Hypoxic/ischemic hepatitis
🔸Cholestatic liver dysfunction
How to diagnose these conditions? 👇🏼👇🏼👇🏼
#livertwitter
1/2To all trainees
@AASLDtweets
trying to figure out their future 🛣️:
I was in your 👠 5 yrs ago. Not all advice is good advice. I received not so good advice right👇🏼in 2017.
U can do what you want, have as many passions as you wish, take on as many roles as you desire
#TLM22
If you are still on the fence about carvedilol and it’s role in compensated patients
Or if you still debate EVL vs NSBB
Review these slides For the answer
👇🏼👇🏼👇🏼
#livertwitter
@BavenoVII
💥Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases💥
@AASLDtweets
@HEP_Journal
#livertwitter
treating alcohol use by
@rabataller
📌 biomarkers of alcohol use
📌 personalized medicine goes beyond genes in alcohol use
📌 motivational interviewing saves lives
📌 role of pharmacologic therapy
WE AS HEPATOLOGISTS NEED TO BE BETTER TRAINED 💯
#livertwitter
#LiverMtg21
Excellent talk by
@ggarciatsao
on portal vein thrombosis
🔑 points:
👉 main impact in
#cirrhosis
-> post
#LT
survival
👉 Treatment indications
- >50%/progressive PVT
- PVT of both branches
- extension into SMV
👉 Don't wait too long for TIPS
#livertwitter
excellent statements on PVT in non-cirrhotic patients
📌consider liver bx /HVPG in those w/abnormal liver test/imaging
📌DOACs can be 1st line except triple+APL
📌long term AC >6 months indications 👇
and the big finale
YES, YOU CAN BAND WHILE ON AC!
#livertwitter
Excellent work 🌎 liver community for removing stigmatization from most common chronic liver dis by creating new nomenclature
#MASLD
Let's continue to ⬆️ awareness, ⬇️ stigma & expedite advancement in 💊 for our patients
#LiverTwitter
@AASLDtweets
Happy Norouz (Spring equinox) to all my
#GItwitter
#livertwitter
friends 😊
May this be a year of health and happiness (the two things we need the most)!
A new study reported that liver dysfunction biomarkers (prolonged PT/INR and aPTT, decreasing factor V activity) should not be used to assess bleeding risk in patients with
#cirrhosis
. Alternative biomarkers need to be developed.
#thrombosis
@CHUVLausanne
If I may provide a piece of advice as a hepatolgist who also scopes to new GI fellows:
Use your procedure note to offer an actual assessment and plan.
Follow up in GI clinic or resume diet is NOT a plan.
Make it a habit from day 1!
#GItwitter
#livertwitter
#tipsfornewdocs
#livertwitter
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
@AmCollegeGastro
🔥Liver Injury in Liver Transplant Recipients with COVID‐19: US Multicenter Experience
Our
#livertwitter
to paper is out
Read the summary 👇🏼
Thankful to all the authors/collaborators &
special thanks to
@BWSadowskiMD
@renumathyd
what to tell my patient with
#NAFLD
?
👉 Mediterranean diet recommended by EASL
👉 Not enough data on IF/low carb diet, if it works for you go for it
👉 🔽 red meat 🔼 fiber
👉 Watch out for sugar: excellent tips from
@DrMTLong
👉 Quantify alcohol use
#livertwitter
@AASLDtweets
updates on autoimmune hepatitis
📌incidence is increasing
📌19-34% ab negative
📌 AIH and NAFLD
📌 increasing incidence of checkpoint hepatitis
#TLMdx
#livertwitter
@AASLDtweets
Role of IR in treatment of
#HCC
summarized by Dr Ed Kim
#livertwitter
@HCCLIVEConf
My 🔥 take:
- Time to share the space with rad onc
- TACE: old and familiar but are we settling for familiar vs effective?
@freddyeescorcia
🚨Will you use
#FIPS
(Freiburg index of post-TIPS survival) to predict risk of
#TIPS
?
Age, bil, albumin & cr ->most significant predictors of 6-months survival post TIPS
superior to the MELD, MELD-Na, CP
@JHepatology
#livertwitter
Important study in
#HCC
detection
🟢Biannual US -> suboptimal performance for early-stage
🔵Annual NC-AMRI ⬆️ diagnostic yield without⬆️ false referral
🔴Alternating biannual US & NC-AMRI⬆️ sensitivity>> biannual US
#livertwitter
@JHepatology
After watching social dilemma on
@netflix
was trying to reassess my relationship with social media!
Then I got👇🏼 as a reminder of all the wonderful people I have met, collaborated with & learned from on twitter
I am more than ever grateful to my
#livertwitter
community 😊
1/2
Updates on management of HRS-AKI with
#FlorenceWong
#livertwitter
#TLM22
@AASLDtweets
⭐️ How does albumin help
⭐️ How to use terlipressin
⭐️ Watch out for respiratory failure
⭐️ Who would not respond well to terlipressin
Great things happen when a team of ambitious, caring, dedicated people come together.
I look at this picture and pinch myself seeing how lucky I am to work with this all star team increasing access to Veterans needing liver and kidney transplant
@bthomas215
@DrJessicaDavis
…
In decompensated patients
- low risk varices->NSBB
- high risk varices-> NSBB preferred over EVL
🚨 attention to those with refractory ascites and low MAP
#LiverTwitter
#portalHTNSig
@BavenoVII
A thread 🧵 to bookmark
Spring 💐 is when new practice guidances come out👇🏼👇🏼👇🏼👇🏼
📣1/3
Non-invasive testing for assessment of portal hypertension
#livertwitter
@AASLDtweets
@HEP_Journal
🔥Fibrates for itch: FITCH🔥
📍PSC, PBC or SSC pts
📍double-blind
📍bezafibrate (400mg/d) or placebo 21 days
📍primary endpoint >50% ⬇️ of pruritus
📍bezafibrate-> endpoint in 45%
📍also ⬇️ serum ALP
📍Mild ⬆️ creatinine
#livertwitter
@AGA_Gastro
Is it cost-effective to treat all HBsAg+ in 🇺🇸
by
#DevinRazavi
-Shearer
🔑 points
- eliminates decompensation
- ⬇️ HCC & HBV related 💀
- can be cost-effective
💭 provoking study
#livertwitter
#LiverMtg21
@AASLDtweets
Is it 🕰 to retire the fancy, complicated hep B algorithms?
One of the best talks I have heard on the role of biopsy in diagnosis, staging and disease monitoring of liver disease by
@ebtapper
Best quote: "We make decisions not tests"
Session: post graduate course
#TLMdx
#livertwitter
6/6
What part of children and teenagers being killed as they are fighting for their freedom does not merit support?
I feel guilty, ashamed and angry. I feel like I am on a different planet.
#Mahsa_Amini
Thank you for reading
Please
#beourvoice
#livertwitter
#gitwitter
To all the undergrads, med students & residents I met over the past few days
@AmCollegeGastro
#ACG2023
📍You are amazing
📍You should be proud of your accomplishments
📍Future of GI is bright
Fortunate to moderate/review your fantastic research
#livertwitter
2/2
✴️Be genuine
✴️Be present
✴️only say yes if you have time and passion about the task
✴️know your strengths
✴️know and avoid imposter syn
#TLM22
#livertwitter
Portal hypertension: An increase in pressure gradient in any segment of the portal venous system. It is classified on the basis of the site of increased vascular resistance: extrahepatic or intrahepatic.
so much hard work has been put into gathering high quality data, summarize them and come up with practical statements👏
I would not do justice by trying to summarize them, so read them below Down pointing backhand index
#LiverTwitter
@BavenoVII
@ggarciatsao
📣Do you want to know more about Terlipressin use in AKI-HRS?
Register for this
@AASLDtweets
#portalHTNSIG
webinar
Thursday, July 20, 12:00 pm - 1:00 pm (EDT)
Moderator: Florence Wong
Presenter: Pratima Sharma
#livertwitter
Congratulations to a true leader, an exceptional example of women supporting women and my good friend
@AnjanaPillaiMD
as newly elected vice chair of liver cancer SIG.
well deserved :)
#livertwitter
@AASLDtweets
Risk of
#HCC
post
#SVR
in F3
🧵
#livertwitter
🔹large cohort, multi center, observational study
🔹stage 3 definition
TE 9.5-14.5 kPa
excluded those with nodular liver surface, splenomegaly, ascites or collaterals on imaging, low plt or varices.